Corey Ritter

Atlas Data Storage is pioneering the use of DNA as a highly durable, low cost permanent data storage medium.

In an era of ever-increasing cost and skills required to do complex diagnostics tests, Enumerix is developing a next-generation genomics platform to make high resolution biology simple, fast, and affordable. Our goal is to reduce the cost of high resolution tests by at least 10 times to enable access to a broader patient population. We believe our team is poised to accomplish this. We are a group of seasoned biotech and innovative entrepreneurs, engineers, and scientists with a proven track record of advancing the field of genomics from innovation to commercial success. We have pioneered DNA microarrays, non-invasive prenatal screening using next generation sequencing (NGS), and high-throughput single-cell NGS, and together the founding team holds over 60 granted patents.

Elephas is developing a technology platform to assess how live tumor cells respond to cancer therapies. We are harnessing the latest advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence to revolutionize cancer treatment. Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite advances in precision medicine and a significant increase in the number of available therapies, many cancer patients still derive no benefit from their treatment. Immunotherapy is an emerging type of treatment that can greatly benefit patients when it is successful. Unfortunately, today only 1 in 3 patients receiving therapy respond and only 1 in 5 receiving immunotherapy respond. We maintain the native 3-dimensional cellular architecture of a patient’s tumor and enable ex-vivo real-time profiling of live tumor samples. The platform is being developed for use with immunotherapy agents alone and in combination with traditional chemotherapy and targeted therapies. THE ELEPHAS MISSION To develop innovative cancer diagnostic products and services that enable accurate prediction of clinical treatment outcomes and accelerate drug development

Slingshot Biosciences is working on an overlooked but ubiquitous problem in healthcare that has a tremendous impact on a variety of patient outcomes: the lack of consistent reference material for cell-based assays. The company’s cell mimics represent a new way to use control material in the workflow, whether for instrument manufacturing, assay setup, and validation or as a manufacturing QC control. Synthetic cell mimics provide a new opportunity for precise, biologically-relevant, and cost-effective controls to aid many healthcare and research efforts globally. Learn more at slingshotbio.com

Quantum Circuits, Inc. (QCI) is developing a full-stack quantum computing platform using superconducting devices and a modular, robust, and scalable architecture. QCIs mission is to build the first truly useful quantum computers. Our novel approach to building quantum computers is based on technology developed over a decade of research at Yale Universitys world-class quantum labs. Our machines have built-in error correction, unique software features that enable lightning-fast algorithm execution, and multiple modes of operation to solve more algorithms than ever, all in one quantum computer.

Single-cell sequencing solutions company, leveraging patented combinatorial indexing technology to enable accessible, scalable and cost effective profiling and analysis across broad range of genomic, transcriptomic, epigenomic, proteomic, and multi-omics applications.

Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company's MERSCOPE Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development.

908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in vital health and safety applications, such as the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning.

Atlas Data Storage is pioneering the use of DNA as a highly durable, low cost permanent data storage medium.

In an era of ever-increasing cost and skills required to do complex diagnostics tests, Enumerix is developing a next-generation genomics platform to make high resolution biology simple, fast, and affordable. Our goal is to reduce the cost of high resolution tests by at least 10 times to enable access to a broader patient population. We believe our team is poised to accomplish this. We are a group of seasoned biotech and innovative entrepreneurs, engineers, and scientists with a proven track record of advancing the field of genomics from innovation to commercial success. We have pioneered DNA microarrays, non-invasive prenatal screening using next generation sequencing (NGS), and high-throughput single-cell NGS, and together the founding team holds over 60 granted patents.

Elephas is developing a technology platform to assess how live tumor cells respond to cancer therapies. We are harnessing the latest advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence to revolutionize cancer treatment. Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite advances in precision medicine and a significant increase in the number of available therapies, many cancer patients still derive no benefit from their treatment. Immunotherapy is an emerging type of treatment that can greatly benefit patients when it is successful. Unfortunately, today only 1 in 3 patients receiving therapy respond and only 1 in 5 receiving immunotherapy respond. We maintain the native 3-dimensional cellular architecture of a patient’s tumor and enable ex-vivo real-time profiling of live tumor samples. The platform is being developed for use with immunotherapy agents alone and in combination with traditional chemotherapy and targeted therapies. THE ELEPHAS MISSION To develop innovative cancer diagnostic products and services that enable accurate prediction of clinical treatment outcomes and accelerate drug development

Slingshot Biosciences is working on an overlooked but ubiquitous problem in healthcare that has a tremendous impact on a variety of patient outcomes: the lack of consistent reference material for cell-based assays. The company’s cell mimics represent a new way to use control material in the workflow, whether for instrument manufacturing, assay setup, and validation or as a manufacturing QC control. Synthetic cell mimics provide a new opportunity for precise, biologically-relevant, and cost-effective controls to aid many healthcare and research efforts globally. Learn more at slingshotbio.com